Praxis Precision Medicines, Inc. (PRAX)

Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NASDAQ
Market cap: $8.35B

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Latest financial period: June 30, 2026
Filed with the SEC: August 6, 2026
Estimated earnings date: November 4, 2026

Not currently ranked. Cannot calculate: sales growth, FCF yield

Menu

Home

Compare

Next Earnings Reports

How this site works

Terms of use

About